These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33280052)

  • 21. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
    Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
    Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus: Influence of the Posttransplant Concentration/Dose Ratio on Kidney Graft Function in a Two-Year Follow-Up.
    Nowicka M; Górska M; Nowicka Z; Edyko K; Edyko P; Wiślicki S; Zawiasa-Bryszewska A; Strzelczyk J; Matych J; Kurnatowska I
    Kidney Blood Press Res; 2019; 44(5):1075-1088. PubMed ID: 31522184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
    Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
    Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients.
    Arreola-Guerra JM; Serrano M; Morales-Buenrostro LE; Vilatobá M; Alberú J
    Ann Transplant; 2016 Feb; 21():105-14. PubMed ID: 26879833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tac-MMF Versus CsA-MMF/CsA-AZA-Based Regimens in Development of De Novo Complement-Binding Anti-HLA Antibodies After Kidney Transplantation.
    Sahutoglu T; Akgul SU; Caliskan Y; Yazici H; Demir E; Kara E; Temurhan S; Savran FO; Turkmen A
    Transplant Proc; 2017 Apr; 49(3):454-459. PubMed ID: 28340811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation.
    Xie W; Fan S; Liu R; Yan W; Su C; Zheng K; Wang X; Wang Z
    Transplant Rev (Orlando); 2024 Jul; 38(3):100842. PubMed ID: 38537484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of
    Mendoza Rojas A; Hesselink DA; van Besouw NM; Baan CC; van Gelder T
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1323-1331. PubMed ID: 31721605
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation.
    Fujiyama N; Satoh S; Saito M; Numakura K; Inoue T; Yamamoto R; Saito T; Nara T; Kanda S; Narita S; Kagaya H; Miura M; Habuchi T
    Int Immunopharmacol; 2019 Nov; 76():105881. PubMed ID: 31520989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation.
    Crespo E; Vidal-Alabró A; Jouve T; Fontova P; Stein M; Mocka S; Meneghini M; Sefrin A; Hruba P; Gomà M; Torija A; Donadeu L; Favà A; Cruzado JM; Melilli E; Moreso F; Viklicky O; Bemelman F; Reinke P; Grinyó J; Lloberas N; Bestard O
    Front Immunol; 2022; 13():869554. PubMed ID: 35833145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of immunosuppressive treatment on homocystein levels in patients after kidney transplantation during a 2 year observation period].
    Aksamit D; Janda K; Kuźniewski M; Krzanowski M; Ignacak E; Betkowska-Prokop A; Chowaniec E; Sułowicz W
    Przegl Lek; 2012; 69(11):1175-9. PubMed ID: 23646442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial.
    Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K
    Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
    Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
    Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.